Last reviewed · How we verify
E2 patch/antagonist
An estradiol (E2) transdermal patch that delivers estrogen while blocking estrogen receptor signaling through an antagonist component.
An estradiol (E2) transdermal patch that delivers estrogen while blocking estrogen receptor signaling through an antagonist component. Used for Menopausal symptoms (investigational combination approach).
At a glance
| Generic name | E2 patch/antagonist |
|---|---|
| Also known as | Climara®, Ganirelix acetate injection® |
| Sponsor | Weill Medical College of Cornell University |
| Drug class | Estrogen receptor antagonist / hormone replacement therapy |
| Target | Estrogen receptor (ER-α, ER-β) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Women's Health |
| Phase | FDA-approved |
Mechanism of action
This combination approach provides estrogen replacement via transdermal delivery while simultaneously antagonizing estrogen receptors, potentially modulating hormone-dependent pathways. The dual mechanism may be designed to achieve therapeutic benefits in conditions where estrogen replacement alone is insufficient or where receptor antagonism provides additional benefit.
Approved indications
- Menopausal symptoms (investigational combination approach)
Common side effects
- Skin irritation at patch site
- Headache
- Breast tenderness
- Nausea
Key clinical trials
- Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction (PHASE4)
- Menopause Effects on Vascular Function (NA)
- Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function (NA)
- Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- E2 patch/antagonist CI brief — competitive landscape report
- E2 patch/antagonist updates RSS · CI watch RSS
- Weill Medical College of Cornell University portfolio CI